Globus Medical (GMED) Stock Price, News & Analysis

Company Overview

Globus Medical, Inc., a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative and congenital conditions, deformity, tumors, and trauma injuries; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives. It also offers products for the treatment of orthopedic trauma, including fracture plates, compression screws, intramedullary nails, and external fixation systems; and hip and knee joint solutions, including modular hip stems and acetabular cups, as well as posterior stabilizing and cruciate retaining knee arthroplasty implants. In addition, the company distributes human cell, tissue, and cellular and tissue-based products. It sells its products through direct or distributor sales representatives, as well as hip and knee products through independent sales agents. Globus Medical, Inc. was incorporated in 2003 and is headquartered in Audubon, Pennsylvania.

Key Stats

• Today's Range: $71.73 to $74.33
• 50-Day Range: $69.61 to $93.25
• 52-Week Range: $49.33 to $94.93
• Volume: 147,922 shs
• Average Volume: 1.02 million shs
• Market Capitalization: $10.22 billion
• P/E Ratio: 99.23
• Dividend Yield: N/A
• Price Target: $97.09
• Consensus Rating: Moderate Buy

Globus Medical Stock Analysis - MarketRank™

Globus Medical scored higher than 99% of companies evaluated by MarketBeat, and ranked 4th out of 930 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Globus Medical has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 9 buy ratings, 3 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Globus Medical has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 17.15%

Earnings Growth

Earnings for Globus Medical are expected to grow by 17.15% in the coming year, from $3.44 to $4.03 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Globus Medical is 97.77, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 22.54.

Price to Earnings Ratio vs. Sector

The P/E ratio of Globus Medical is 97.77, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 23.42.

Price to Earnings Growth Ratio

Globus Medical has a PEG Ratio of 1.61. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Globus Medical has a P/B Ratio of 2.50. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.18% of the float of Globus Medical has been sold short.

Short Interest Ratio / Days to Cover

Globus Medical has a short interest ratio ("days to cover") of 1.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Globus Medical has recently decreased by 7.63%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Globus Medical does not currently pay a dividend.

Dividend Growth

Globus Medical does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.1 / 5
• Environmental Score: -0.93

Percentage of Shares Shorted

2.18% of the float of Globus Medical has been sold short.

Short Interest Ratio / Days to Cover

Globus Medical has a short interest ratio ("days to cover") of 1.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Globus Medical has recently decreased by 7.63%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 3.7 / 5
• News Sentiment: 1.60

News Sentiment

Globus Medical has a news sentiment score of 1.60. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.72 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 14 news articles for Globus Medical this week, compared to 9 articles on an average week.

Search Interest

Only 4 people have searched for GMED on MarketBeat in the last 30 days. This is a decrease of -20% compared to the previous 30 days.

MarketBeat Follows

13 people have added Globus Medical to their MarketBeat watchlist in the last 30 days. This is an increase of 86% compared to the previous 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Globus Medical insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,250,804.00 in company stock.

Percentage Held by Insiders

18.54% of the stock of Globus Medical is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

95.16% of the stock of Globus Medical is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

GMED Stock Analysis - Frequently Asked Questions

How have GMED shares performed this year?

Globus Medical's stock was trading at $82.71 at the start of the year. Since then, GMED stock has decreased by 11.3% and is now trading at $73.3290.
View the best growth stocks for 2025 here.

How were Globus Medical's earnings last quarter?

Globus Medical, Inc. (NYSE:GMED) released its earnings results on Thursday, February, 20th. The medical device company reported $0.84 earnings per share for the quarter, topping the consensus estimate of $0.74 by $0.10. The medical device company had revenue of $657.29 million for the quarter, compared to analysts' expectations of $646.19 million. Globus Medical had a net margin of 4.09% and a trailing twelve-month return on equity of 10.83%.

How do I buy shares of Globus Medical?

Shares of GMED stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Globus Medical own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Globus Medical investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), CrowdStrike (CRWD), Arista Networks (ANET), Advanced Micro Devices (AMD) and ServiceNow (NOW).

Company Calendar

• Last Earnings: 2/20/2025
• Today: 4/02/2025
• Next Earnings (Estimated): 5/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: Surgical & medical instruments
• Sub-Industry: Health Care Equipment
• Current Symbol: NYSE:GMED
• CIK: 1237831
• Web: www.globusmedical.com
• Phone: (610) 930-1800
• Fax: 610-930-2042
• Employees: 2,600
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $97.09
• High Stock Price Target: $115.00
• Low Stock Price Target: $82.00
• Potential Upside/Downside: +32.4%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.75
• Research Coverage: 12 Analysts

Profitability

• EPS (Most Recent Fiscal Year): $0.75
• Trailing P/E Ratio: 97.77
• Forward P/E Ratio: 21.32
• P/E Growth: 1.61
• Net Income: $122.87 million
• Net Margins: 4.09%
• Pretax Margin: 4.88%
• Return on Equity: 10.83%
• Return on Assets: 8.63%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.51
• Quick Ratio: 1.64

Sales & Book Value

• Annual Sales: $2.52 billion
• Price / Sales: 4.00
• Cash Flow: $3.14 per share
• Price / Cash Flow: 23.32
• Book Value: $29.32 per share
• Price / Book: 2.50

Miscellaneous

• Outstanding Shares: 137,542,000
• Free Float: 110,922,000
• Market Cap: $10.09 billion
• Optionable: Optionable
• Beta: 1.19